- March 10, 2026
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Announces Personnel Changes
Taiho Pharmaceutical Co., Ltd. announced today that the changes of directors detailed below have been determined at the Annual General Shareholders’ Meeting and the Board Meeting held on March 9.
Particulars
| Name | Title |
| Masayuki Kobayashi | President and Representative Director |
| Atsushi Azuma | Managing Director, Board Member Corporate Management and Administration, Quality and Reliability Assurance, Business Development, Portfolio Management, Finance & Accounting |
| Tatsuya Niki | Managing Director, Board Member Consumer Healthcare Business, General Affairs |
| Takeshi Sagara | Executive Director, Board Member Medical Affairs, Translational Development, Clinical Development, Discovery and Preclinical Research |
| Noriyuki Takahashi | Executive Director, Board Member Corporate Planning, Digital & IT, Ethical Drug Sales and Marketing |
| Yuichi Ozeki (new appointment) |
Executive Director, Board Member Pharmaceutical Technology |
| Nobuyuki Hashimoto | Standing Audit & Supervisory Board Member |
| Yasunori Okada | Standing Audit & Supervisory Board Member |
| Tatsuya Nakajima | Outside Audit & Supervisory Board Member |
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.